Valeant's meltdown claims another top exec, this time at shareholder Sequoia

Sequoia Fund chief Robert Goldfarb bowed out of his post Wednesday after his big bet on Valeant Pharmaceuticals ($VRX) turned up sour. One of the embattled drugmaker's biggest shareholders, Sequoia at one point had 30% of its capital tied up in Valeant, MarketWatch reports. Report

Suggested Articles

Novavax has inked a $60 million contract with the U.S. Department of Defense to help fund U.S.-based manufacturing of its COVID-19 vaccine candidate.

Since the Warp Speed selections went public, experts have been wondering why some drugmakers were left off.

Vaccine maker Inovio has accused a longtime manufacturing partner of hampering its efforts to produce 1 million doses of a potential COVID-19 vaccine.